Science:Life Sciences
In the first Biotech Hangout of 2024, RA Capital’s Peter Kolchinsky joins hosts Daphne Zohar, Josh Schimmer, Tim Opler, Paul Matteis and Luba Greenwood to discuss the latest biotech news. They start with the last M&A deals of 2023 including Bristol Myers Squibb’s acquisition of Karuna and Rayzebio, and AstraZeneca’s acquisition of Gracell. They discuss insights from RA Capital’s latest sector analysis and the outlook for the sector in 2024, plus JPM predictions. The hosts also cover news from the first week of 2024 including Longboard Pharmaceuticals and Dyne Therapeutics data, Novartis’ expanded collaboration with Voyager, the FDA’s hold on Iovance’s TIL therapy and their approval of AstraZeneca and Ionis’ rare nerve disease treatment. Other topics include Goldman Sachs life science investment fund and ImmunityBio’s royalty financing. *This episode aired on January 5, 2024
More Episodes
2023-10-25
2023-10-16
2023-10-16
2023-10-04
2023-10-03
2023-09-22
2023-09-14
2023-08-29
2023-08-17
2023-08-09
2023-08-01
2023-08-01
2023-07-20
2023-07-03
2023-06-23
2023-06-14
2023-06-06
2023-05-24
2023-05-16
2023-05-02
Get this podcast on your
phone, FREE
